Search

everythinglearnresearchcommunity

for

Search:↓

A 52-year-old shared positive hair regrowth results after using finasteride for 24 months, with noticeable improvements after 13-14 months, and recently added oral minoxidil to the regimen. Users discussed the effectiveness of combining finasteride, minoxidil, and sometimes dutasteride for better hair growth results.

The conversation discusses the use of RU58841 for hair loss, focusing on its side effects, standardization issues, and user experiences. The user also inquires about the use of other treatments like minoxidil, finasteride, and microneedling.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A user increased their RU58841 treatment from 5% to 8% to combat hair loss and is questioning the effectiveness of the higher dosage. Another user shared their extensive hair loss treatment regimen, suggesting that while 8% RU58841 might not significantly change results, it's worth trying as individual responses vary.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation is about whether 0.5 mg of finasteride reduces scalp DHT as effectively as 1 mg. Users suggest that even lower doses like 0.05 mg can significantly reduce scalp DHT.

A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.

A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

Concerns about the effectiveness of DHT inhibitors like finasteride and minoxidil due to potential polymorph issues. Experts suggest these concerns are largely unfounded, especially compared to rare cases like ritonavir.

The user is considering switching from finasteride to dutasteride for hair loss treatment and is unsure when to stop finasteride. Dutasteride takes about 15 days to reach significant DHT suppression compared to finasteride.

Dutasteride 0.5 mg significantly reduces both scalp and hair follicle DHT, with a greater reduction in hair follicle DHT. The discussion questions which reduction is more important for androgenetic alopecia and diffuse thinning.

Higher doses of dutasteride reduce scalp DHT more effectively than finasteride, but have diminishing returns after 3mg daily and may cause more side effects. Combining dutasteride with topical minoxidil can enhance results, but using both finasteride and dutasteride together is unnecessary.

Switching from topical to oral minoxidil may lead to better results for some users, with oral minoxidil generally being more effective due to higher absorption. However, it can also cause side effects like hypertrichosis and blood pressure issues, and individual responses may vary.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

A user is seeking advice on hair loss treatment and has been prescribed finasteride. They currently use minoxidil, rosemary oil, and castor oil, and are considering adding dermarolling. Respondents suggest daily use of minoxidil and finasteride, with some recommending additional treatments like ketoconazole shampoo, dermapen, dutasteride, and vitamins.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

The user is experiencing continued hair loss despite using dutasteride and oral minoxidil, and is considering adding finasteride or adjusting their current treatment. They are seeking advice on whether to change their approach due to lack of improvement, especially at the temples and crown.

Dutasteride at 0.5mg blocks 50% of scalp DHT, while higher doses like 1mg and 2.5mg block more, with 2.5mg blocking up to 80%. Some users report better results with lower doses, and there's confusion about the effectiveness of different dosages on scalp versus serum DHT.

A 22-year-old male experienced hair regrowth using an intermittent Dutasteride regimen, oral and topical Minoxidil, FolliHair AM/PM, and Salicia KT shampoo. He stopped Dutasteride due to side effects like dry eyes and skin, but noticed increased hair shedding after stopping.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The user is using 5% Minoxidil and 0.1% topical Finasteride and is considering adding 0.5mg Dutasteride every 5 days to stabilize hair regrowth. Consistency with treatment is advised, and there is no strong evidence linking Finasteride or Dutasteride to fertility issues.

The user is considering starting dutasteride (DUT) 0.5mg for hair loss due to lack of access to finasteride and is concerned about potential side effects. They seek guidance on whether to begin this treatment.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

A 20-year-old with anxiety and depression is considering finasteride for hair loss but is worried about potential side effects. They decide to consult a doctor and consider starting with a low dose, while also exploring topical finasteride as a potentially safer option.

Switching finasteride brands from Teva to Proscar led to hair and skin issues, suggesting possible differences in effectiveness or quality. Users recommend returning to the original brand that worked well.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

A user reported significant hair improvement after one month of using dutasteride and oral minoxidil. Others expressed skepticism, attributing perceived changes to lighting and styling, and debated the effectiveness and risks of these treatments.